

RNS Number : 8606H
Aptamer Group PLC
22 March 2024

22 March 2024

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Notice of Results and Investor Presentation

Aptamer Group plc (AIM: APTA), the developer of novel Optimer[®] binders to enable innovation in the life sciences industry, will announce its interim results for the six months ended 31 December 2023 on 28 March 2024.

The Company is pleased to announce that Dr Arron Tolley (Chief Technical Officer), Dr David Bunka (Chief Scientific Officer) and Andrew Rapson (Chief Financial Officer) will provide a live presentation relating to the Interim Results via Investor Meet Company on 28 March 2024 at 15:00 GMT.

The live presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 27 March 2024 at 09:00 GMT, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Aptamer Group Plc via:

<https://www.investormeetcompany.com/aptamer-group-plc/register-investor>

Investors who already follow Aptamer Group Plc on the Investor Meet Company platform will automatically be invited.

- ENDS -

For further information, please contact:

Aptamer Group plc Steve Hull	+44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Mark Brady / Adam Dawes	+44 (0) 20 3368 3550
Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker	+44 (0) 20 3657 0050

About Aptamer Group plc

Aptamer [Group](#) develops custom affinity binders through its proprietary Optimer[®] platform to enable new approaches in therapeutics, diagnostics, and research applications. The Company strives to deliver transformational solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an antibody alternative. The global affinity ligand market is currently worth over \$170 billion.

Aptamer has successfully delivered projects for a range of global pharma companies, diagnostic development companies, and research institutes, covering multiple application areas with the objective of establishing royalty-bearing licenses.

information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORBRGDXBBDDGSB